Skip to main content

Table 2 Relative hazard of death in HNSCC patients based on platelet counts

From: Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma

Variables

Low (<150) N = 67

Low normal (150-229) N = 361

Mid-normal (230-314) N = 379

High normal (315-399) N = 169

HIGH (≥400) N = 75

Number dead (%)

37 (55)

150 (42)

146 (39)

105 (62)

53 (71)

Median Survival Months (95% CI)

37.7 (20.7- 84.8)

64.0 (53.6-78.9)

74.7 (60.7 100.4)

23.8 (17.7 - 36.7)

16.3 (11.8 -29.2)

p-value for difference

    

<0.0001

Overall Survival

     

Unadjusted HR (95% CI)

1.52 (1.06-2.18)

1.07 (0.85-1.34)

1.0 (reference)

1.98 (1.54-2.55)

2.64 (1.92 -3.61)

Adjusted HR (95% CI)

1.50 (0.96-2.35)

1.25 (0.93-1.68)

1.0 (reference)

2.20 (1.58-3.05)

2.37 (1.60-3.50)

HR (95% CI) by Stage

     

I (n = 103)

0.41 (0.05-.3.31)

1.18 (0.33-4.20)

1.0 (reference)

1.60 (0.27-9.54)

0.35 (0.03-4.18)

II (n = 95)

1.99 (0.52-7.67)

1.40 (0.57-3.38)

1.0 (reference)

1.54 (0.48-4.99)

1.83 (0.45-7.40)

III (n = 146)

0.74 (0.16-3.40)

1.32 (0.62-2.82)

1.0 (reference)

2.43 (0.91-6.50)

1.86 (0.53-6.45)

IV (n = 478)

2.33 (1.34-4.10)

1.18 (0.78-1.78)

1.0 (reference)

2.50 (1.66-3.76)

2.47 (1.55-2.93)

  1. Adjusted model controls for age, race, site, grade, treatment, smoking and stage.
  2. P for interaction between stage and classes of platelets p = 0.31.